2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 388-390
Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Biological Processes, Immune Mechanism, Diseases, Immunology, GVHD, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Research, AML, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

567 Post-transplant cyclophosphamide is associated with differences in acute gvhd organ distribution and severity after HLA-matched unrelated donor hematopoietic cell transplantation compared with calcineurin inhibitor- based gvhd prophylaxis

Rima M. Saliba, PhD, Tao Wang, PhD2, Cuyler Huffman, MS3, Pooja Khandelwal, MD4, Nosha Farhadfar, MD5, Zachariah Defilipp, MD6, Arpita Gandhi, M.D., M.S.7, Fotios Michelis, MD, PhD8, Monzr M. M Al Malki, MD9, Stephen R. Spellman, MBS10, Stephanie J. Lee Jr, MD, MPH11, Najla El Jurdi, MD12, Rohtesh Mehta, MD, MPH13
1 Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, United States
2 CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, United States, Division of Biostatistics, Data Science Institute, Medical College of Wisconsin, Milwaukee, United States
3 CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, United States
4 Department of Pediatrics, University of Cincinnati,, Cincinnati, United States, Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cinncinnati, United States
5 Sarah Cannon Transplant & Cellular Program at Methodist Hospital, San Antonio, United States
6 Hematopoietic Cell Transplant and Cellular Therapy Program, Mass General Brigham Cancer Institute, Boston, United States
7 Oregon Health and Science University, Portland, United States
8 Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada
9 City of Hope Cancer Center, Duarte, United States
10 CIBMTR® (Center for International Blood and Marrow Transplant Research), NMDP, Minneapolis, United States
11 Fred Hutchinson Cancer Center, Seattle, United States
12 CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, United States, Immune Deficiency and Cellular Therapy Program, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, United States
13 CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, United States, Stem Cell Transplantation and Cellular Therapies, University of Texas, MD Anderson Cancer Center, Houston, United States

Background. Post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GvHD) prophylaxis is associated with a lower incidence of grade (gr) 3-4 acute (a) GvHD than calcineurin-inhibitor (CNI) based prophylaxis after allogeneic hematopoietic cell transplant (HCT). It remains unknown, however, whether PTCy and donor type independently impact the clinical presentation of aGvHD. Here, we evaluated the association between GvHD prophylaxis/donor type, and organ involvement and severity among patients diagnosed with gr 1-4 aGvHD using the CIBMTR database.

Methods. Adult patients who underwent first HCT in the US (2014-2022) for AML or ALL in CR1 or CR2, or MDS with PTCy- or CNI/methotrexate (MTX)-based GvHD prophylaxis (without ATG) were eligible. Patients diagnosed with gr 1-4 aGvHD after peripheral blood HCT were included. The objectives were to compare aGvHD organ distribution and severity: 1) according to prophylaxis (PTCy vs CNI/MTX) in HLA-matched (8/8) unrelated (MUD) and -matched sibling donor (MSD) HCT and 2) according to donor type [MUD, MSD, haploidentical (Haplo), and (7/8)-matched unrelated (MMUD)] among recipients of PTCy prophylaxis. Organ involvement and stage [stg] distributions were compared in univariate analysis using descriptive statistics. Statistical significance was set at .01 level and marginal significance at .05 to account for multiple testing.

Results. 2498 patients diagnosed with gr 1-4 aGvHD were included with the following donor/prophylaxis grouping: 854 MUD/CNI/MTX, 212 MUD/PTCy, 560 MSD/CNI/MTX, 56 MSD/PTCy, 704 Haplo/PTCy and 112 MMUD/PTCy. The respective median recipient age (years) was 63, 65, 60, 61, 59, and 63. AML was the most common indication for HCT (42-55%) except the MUD/CNI/MTX, where MDS (46%) slightly exceeded AML (41%). Refined disease risk index was intermediate in >50% of patients. Reduced-intensity conditioning regimens were most common (48-59%) except for Haplo/PTCy with 42% and 39% receiving myeloablative and non-myeloablative regimens, respectively. Overall, maximum reported aGvHD gr was 1 (27%), 2 (47%), 3 (17%), and 4 (10%). Skin (69%), liver (12%), lower (L, 37%) and upper (U, 35%) gastrointestinal (GI) aGvHD were reported. PTCy vs CNI/MTX was associated with >50% reduction in the proportion of gr 4 aGvHD for MUD (6 vs 14%, P=0.002) and MSD (4 vs 13%, P=.05). PTCy was not associated with the proportion of gr 2 or 3 aGvHD in MUD (47 vs 46%, 13 vs 18%) or in MSD (46 vs 43%, 21 vs 20%), respectively. Among MUD, PTCy vs CNI/MTX was not associated with the proportion of skin (71 vs 74%), LGI (34 vs 39%) or UGI (35 vs 39%) aGvHD, but it was associated with significantly lower proportion of liver aGvHD (5 vs 13%, P=.001). Among MUD, PTCy was associated with lower proportion of severe (stg 3-4) skin (18 vs 28%, P=.004) and LGI (11 vs 17%, P=.04) aGvHD. The small (n=11) sample size of liver aGvHD with PTCy precluded meaningful comparison by stg. Among MSD, PTCy vs CNI/MTX was not associated with the proportion of skin (68 vs 69%, P=.8), liver (14 vs 17%, P=.6), LGI (38 vs 42%, P=.55), or UGI (32 vs 39%, P=.3) aGvHD. Similarly, no differences were observed in organ stg. Among recipients of PTCy prophylaxis, donor type was not significantly associated with aGvHD characteristics. The distribution of maximum gr 2, 3, and 4 aGvHD was not different: 47%, 13%, and 6% in MUD; 46%, 21%, and 4% in MSD; 49%, 15%, and 6% in Haplo; and 52%, 12%, and 6% in MMUD, respectively, with no differences in the proportion of gr 2-4 (P=.66) or 3-4 (P=.7) aGvHD. Overall, organ stg distribution did not differ across donor types for skin (P=.06), liver (P=.27), LGI (.78), or UGI (.10).  The respective distributions of organ involvement were 71%, 68%, 76%, and 70% for skin; 5%, 14%, 9%, and 5% for liver; 34%, 38%, 33%, and 30% LGI; and 35%, 32%, 27%, and 35% for UGI. A higher proportion of stg 3–4 skin involvement was observed with increasing HLA disparity, ranging from 13% among MSD recipients to 24% among Haplo recipients (P= .02).

Conclusion: Once MUD patients develop aGVHD, recipients of PTCy prophylaxis had a lower proportion of overall gr 4 aGvHD, any liver, stg 3-4 skin, and stg 3-4 lower LGI involvement compared with CNI/MTX. No significant differences in MSD patients developing aGVHD between CNI/MTX and PTCy were noted. Among PTCy recipients, no significant differences in organ involvement or severity were noted by donor type.

Rima M. Saliba, PhD: No relevant conflicts of interest to declare.